MA. ANTONIA
SALUD SALVIA
TEU
![Foto de MA. ANTONIA](/img/nophoto.png)
![Foto de Hospital del Mar](/img/noimage_org.png)
Hospital del Mar
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital del Mar (9)
2023
-
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402
Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1497-1505
2022
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2021
-
Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: A biomarker study from the GEMCAD 1402 trial
Clinical Cancer Research, Vol. 27, Núm. 10, pp. 2890-2898
2020
-
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected
Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. e110-e116
2019
-
Clinical impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer treated with first-line chemotherapy plus anti–epidermal growth factor receptor therapy
JCO Precision Oncology, Vol. 3
-
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy before Standard Chemoradiotherapy and Surgery in Patients with High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial
JAMA Oncology, Vol. 5, Núm. 11, pp. 1566-1573
2017
-
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: Long-term results from the GEMCAD 0801 trial
Annals of Oncology, Vol. 28, Núm. 2, pp. 344-353
2015
-
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial
Annals of Oncology, Vol. 26, Núm. 8, pp. 1722-1728